RT Journal Article
SR Electronic
T1 Sorafenib plus Daily Low-dose Temozolomide for Relapsed Glioblastoma: A Phase II Study
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3487
OP 3494
VO 33
IS 8
A1 ZUSTOVICH, FABLE
A1 LANDI, LORENZA
A1 LOMBARDI, GIUSEPPE
A1 PORTA, CAMILLO
A1 GALLI, LUCA
A1 FONTANA, ANDREA
A1 AMOROSO, DOMENICO
A1 GALLI, COSTANZA
A1 ANDREUCCETTI, MICHELE
A1 FALCONE, ALFREDO
A1 ZAGONEL, VITTORINA
YR 2013
UL http://ar.iiarjournals.org/content/33/8/3487.abstract
AB Background: Bevacizumab has provided encouraging results in relapsed glioblastoma multiforme (GBM). Pre-clinical and clinical investigations also showed that continuous low-dose temozolomide has some antiangiogenic activity. Based on this evidence, a phase II trial was designed to investigate an oral regimen of sorafenib, an oral multikinase inhibitor, and metronomic temozolomide for relapsed GBM. Patients and Methods: Forty-three patients (median age=60.0 years) naive for antiangiogenic agents received 400 mg sorafenib twice daily plus TMZ 40 mg/m2/day until disease progression. Results: Toxicity, mostly grade 1-2, was manageable. Grade 3-4 toxicities were hand-foot syndrome (n=4), hypertension (n=2), and fatigue (n=3). Five patients (12%) achieved partial response, 18 (43%) stable disease, 20 (48%) showed progression. The median time-to-progression was 3.2 months, 6-month progression-free survival was 26%, and median overall survival was 7.4 months. Conclusion: This combination of sorafenib and temozolomide was feasible and safe, showing some activity in patients with relapsed GBM.